Abstract Background Around 20–30% of all prescribed drugs are estimated to be
metabolised by the cytochrome P450 (CYP) 2D6 enzyme. In a medical practice, it is usually …

Background: Despito a large number of studies investigating the potential clinical relevance
of CYP2D6 genotyping in preventing treatment failure (eg, insufficient efficacy and/or …

Background. Pharmacogenetic testing is used to reveal genetic causes of variation in drug
response. There is limited documentation of the usefulness of this kind of testing in ordinary …

Abstract CYP2C19 and CYP2D6 are important drug-metabolizing enzymes that are involved
in the metabolism of around 30% of all medications. Importantly, the corresponding genes …

The cytochrome P450 (CYP) enzyme family catalyses the metabolism of approximately 80%
of all medications. 1, 2 Many genes encoding the CYP enzymes exhibit high levels of …

Aim: This study was performed in a sample of the Dutch population to estimate the
prevalence of noncoding mutations of CYP2D6 and CYP2C19 as obtained by genotyping. In …

Background Polymorphisms in drug metabolizing enzymes are considered as a major factor
influencing the incidence of adverse drug reactions or failure of pharmacotherapy. Our aim …

The cytochrome P450 (CYP) enzyme family catalyses the metabolism of approximately 80%
of all medications. 1, 2 Many genes encoding the CYP enzymes exhibit high levels of …

Purpose A number of institutions have clinically implemented CYP2D6 genotyping to guide
drug prescribing. We compared implementation strategies of early adopters of CYP2D6 …

The seminal paper on the CYP2D6 Activity Score (AS) was first published ten years ago
and, since its introduction in 2008, it has been widely accepted in the field of …